Catalyst
Slingshot members are tracking this event:
Mallinckrodt (MNK) to complete Phase 3 study of UVADEX® and ECP for Pediatric Patients with Graft Versus Host Disease in Q1 2017
- Source Link:
- https://clinicaltrials.gov/show/NCT02524847
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MNK |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 30, 2019
Occurred Source:
https://clinicaltrials.gov/ct2/show/NCT02524847
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Graft Vs Host Disease, Steroid Refractory Gvhd, Phase 3 Study, Uvadex, Ecp, Methoxsalen, Single Group Assignment, Open Label, Cellex Photopheresis System
